Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Saved in:
| Title: | Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. |
|---|---|
| Authors: | Wu, Yi-Long1 syylwu@live.cn, Cheng, Ying2, Zhou, Xiangdong3, Lee, Ki Hyeong4, Nakagawa, Kazuhiko5, Niho, Seiji6, Tsuji, Fumito7, Linke, Rolf8, Rosell, Rafael9, Corral, Jesus10, Migliorino, Maria Rita11, Pluzanski, Adam12, Sbar, Eric I13, Wang, Tao14, White, Jane Liang14, Nadanaciva, Sashi14, Sandin, Rickard15, Mok, Tony S16 |
| Source: | Lancet Oncology. Nov2017, Vol. 18 Issue 11, p1454-1466. 13p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
